{
}
UBS has raised its target price for Amazon.com, Inc. from $230 to $264, maintaining a Buy rating due to the company's enhancements in one-day and same-day Prime delivery and growth in high-margin revenue streams like ad-supported Prime Video. The average price target from 65 analysts stands at $237.24, with estimates ranging from $180.00 to $285.00. However, GuruFocus estimates a GF Value of $181.39 for Amazon in one year, indicating a potential downside of 21.53% from the current price of $231.15.
UBS has raised its target price for Amazon.com, Inc. from $230 to $264, maintaining a Buy rating due to the company's enhancements in one-day and same-day Prime delivery and growth in high-margin revenue streams like ad-supported Prime Video. The average price target from 65 analysts stands at $237.24, with estimates ranging from $180.00 to $285.00. However, GuruFocus estimates a GF Value of $181.39 for Amazon in one year, indicating a potential downside of 21.53% from the current price of $231.15.
Intel's stock is currently undervalued, trading at just 1.6 times sales and 0.9 times book value, despite significant investments in chip-making infrastructure. The company is pivoting towards a foundry business model, which could lead to substantial long-term growth as demand for AI hardware rises. While it may not regain its former dominance, Intel is positioned for potential market-beating returns in the coming years.
Solana's network activity surged to a record 66.9 million daily transactions, driven by the debut of the Pudgy Penguins NFT project and its native token, PENGU. This milestone eclipsed the total transactions of all other major blockchains combined. Despite a strong start, PENGU's market cap fell from $2.3 billion to $2 billion, while Solana's SOL token rose 3.2% to $229 before retreating to $217 amid market caution ahead of the Fed rate decision.
UBS has raised its price target for Microsoft, maintaining a 'Buy' recommendation despite a temporary drop in the share price, which fell 0.54% to $452.00 on NASDAQ. The outlook suggests further potential for the tech giant.
Roche has launched the cobas Mass Spec, a groundbreaking device for mass spectrometry that has received CE Mark approval. This innovative solution will provide over sixty analytical tests, enhancing patient care by enabling earlier detection of therapeutic responses, particularly in breast cancer patients undergoing hormonal therapy. The technology promotes automation and sustainability in laboratory workflows, aligning with Roche's strategic integration of clinical chemistry and immunochemistry testing.
Nestle has launched protein shots in the U.S. aimed at weight-loss drug users, designed to suppress appetite by mimicking the GLP-1 hormone. The Boost Pre-Meal Hunger Support drink, containing whey protein and low calories, is intended to be consumed before meals and is priced at $10.99 for a pack of four. While it may enhance GLP-1 release, experts question its long-term effectiveness compared to traditional weight-loss medications.
Raiffeisen Bank International AG analyst Alexander Frank maintains a Buy recommendation for IBM shares, raising the price target to USD 250.00. The company is expected to leverage advancements in optics and artificial intelligence, particularly in its strong software segment, potentially exceeding current outlooks. Ongoing research and development efforts are anticipated to positively impact performance in the coming quarters.
US inflation has decreased this year, influenced by the owners' equivalent rent, which does not reflect actual consumer spending power. The Fed, having been slow to cut rates, is expected to proceed cautiously next year, especially amid uncertainties from potential sales taxes under President-elect Trump. Meanwhile, the UK may also lower rates gradually due to deflation in input producer prices, while the ECB's consumer price inflation figures remain stable and largely unreactive.
BioAge Labs has announced a multi-year collaboration with Novartis to discover novel therapeutic targets for age-related diseases, leveraging BioAge's extensive human longevity data and Novartis's expertise in exercise biology. The partnership includes up to $20 million in upfront payments and research funding, with potential future milestones totaling up to $530 million. This collaboration aims to explore the biological mechanisms of aging and the benefits of physical exercise to develop transformative therapies.
USA
Country
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
UBS Raises Amazon Target Price to 264 Amid Delivery Expansion
15:45 18.12.2024
ubs raises amazon target price to 264 amid delivery expansion efforts
15:45 18.12.2024
intel's undervalued stock poised for recovery amid ai demand surge
United States Dollar
NVIDIA Corporation
Taiwan Semiconductor Manufacturing Co Ltd
Samsung E&A Co., Ltd.
Super Micro Computer, Inc.
Mobileye Global Inc.
TWN
USA
David Zinsner
Patrick P. Gelsinger
Show more
15:37 18.12.2024
solana achieves record 66.9 million daily transactions as pengu token launches
15:35 18.12.2024
ubs raises microsoft price target despite recent share decline
15:34 18.12.2024
Roche launches cobas Mass Spec to enhance clinical mass spectrometry testing
15:30 18.12.2024
Nestle introduces protein shots to support weight loss and appetite control
United States Dollar
Eli Lilly and Company
Nestlé S.A.
Walmart Inc.
Novo Nordisk A/S
GBR
USA
CHE
Stefan Palzer
Lora Heisler
Show more
15:24 18.12.2024
IBM Shares Recommended for Buy with Price Target Raised to 250 USD
15:17 18.12.2024
Fed signals rate cuts amid inflation concerns and economic uncertainties
15:14 18.12.2024
bioage labs partners with novartis to target age-related diseases through research
15:11 18.12.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Industry Mergers & Acquisitions
Finance Mergers & Acquisitions
Global Financial Events
Banking Regulations
Workplace Trends
Retail and Consumer Goods
CEO Changes
Domestic Politics
Market Analysis and Predictions
Government Policies
Global Trade Developments
Central Bank Actions
Startups & Entrepreneurship
Elections & Campaigns
Hedge Funds & Private Equity
Supply Chain Management
Financial Scams and Security
Countries:
Companies:
Tesla, Inc.
JPMorgan Chase & Co.
Barclays PLC
Deutsche Bank Money Market PP
UniCredit S.p.A.
Banco BPM S.p.A.
Credit Suisse Lux Digital Healt
Bank of America Corporation
Apple Inc.
BNP Paribas SA
UBS Group AG
The Goldman Sachs Group, Inc.
Banco Santander, S.A.
Commerzbank AG
Credit Suisse Strategic Income I
CREDIT AGRICOLE
SpaceXCoin USD
Lloyds Banking Group plc
Wells Fargo & Company
Amazon.com, Inc.
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Indian Rupee
Japanese Yen
South Korean Won
Danish Krone
Hong Kong Dollar
Australian Dollar
Offshore Chinese Yuan
Canadian Dollar
Mexican Peso
Singapore Dollar
Norwegian Krone
Filipino Peso
Indonesian Rupiah
Russian Ruble
Chilean Peso
People: